Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

8. april 2010 oppdatert av: Eli Lilly and Company

A Randomized Phase II Trial of Two Dose Schedules of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-small Cell Lung Cancer

The purpose of the study is to determine if the combination of cetuximab, carboplatin and paclitaxel will shrink a specific type of lung cancer known as non-small cell lung cancer (NSCLC). The safety of this combination will also be evaluated.

Studieoversikt

Status

Fullført

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Lung cancer is the second most common cancer diagnosed for both genders in the United States. Approximately 173,770 new cases are estimated for 2004. It is the leading cause of cancer deaths in both men and women, with approximately 160,440 deaths estimated for 2004. Prognosis for many is poor if not diagnosed at an early stage, and therapy for advanced disease is limited. The study will test two chemotherapy agents, carboplatin and paclitaxel, in combination with a newly approved drug called cetuximab, which is continuing to be tested in colorectal cancer and other cancers. Cetuximab is a monoclonal antibody, which is believed to work by attaching to an epidermal growth factor receptor (EGFR) on tumor cells and thereby blocking tumor cells from reproducing. It is an antibody to the EGFR. Fifty percent of lung cancers overexpress EGFR.

Rationale:

The present study is built upon the data from previous studies, incorporating cetuximab into each of two regimens of paclitaxel plus carboplatin. The results of prior studies using paclitaxel and carboplatin demonstrate that these drugs in combination, using a variety of schedules, are both safe and effective as therapy for advanced or metastatic NSCLC. The addition of biologic therapy with the anti-EGFR agent cetuximab to the combination will presumably maximize the therapeutic index while keeping toxicity to a minimum in patients with Stage IIIB/IV NSCLC.

Research Hypothesis:

Subjects with previously-untreated stage IIIB/IV NSCLC who receive a combination of paclitaxel, carboplatin, and cetuximab will have a progression-free survival rate greater than that previously reported for subjects receiving the combination of paclitaxel and carboplatin.

Studietype

Intervensjonell

Registrering (Faktiske)

165

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

  • Forente stater
    • California
      • Los Angeles, California, Forente stater, 90089
        • ImClone Investigational Site
      • Santa Monica, California, Forente stater, 90404
        • ImClone Investigational Site
    • Delaware
      • Newark, Delaware, Forente stater, 19713
        • ImClone Investigational Site
    • Florida
      • Orlando, Florida, Forente stater, 32804
        • ImClone Investigational Site
      • St. Petersburg, Florida, Forente stater, 33705
        • ImClone Investigational Site
    • Georgia
      • Tucker, Georgia, Forente stater, 30084
        • ImClone Investigational Site
    • Indiana
      • Terra Haute, Indiana, Forente stater, 47804
        • ImClone Investigational Site
    • Kentucky
      • Louisville, Kentucky, Forente stater, 40202
        • ImClone Investigational Site
    • Maryland
      • Baltimore, Maryland, Forente stater, 21204
        • ImClone Investigational Site
    • Michigan
      • Ypsilanti, Michigan, Forente stater, 48197
        • ImClone Investigational Site
    • New Jersey
      • Newark, New Jersey, Forente stater, 07112
        • ImClone Investigational Site
    • North Carolina
      • Chapel Hill, North Carolina, Forente stater, 27599
        • ImClone Investigational Site
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19141
        • ImClone Investigational Site
    • South Carolina
      • Columbia, South Carolina, Forente stater, 29209
        • ImClone Investigational Site
    • Tennessee
      • Knoxville, Tennessee, Forente stater, 37920
        • ImClone Investigational Site
    • Texas
      • Houston, Texas, Forente stater, 77024
        • ImClone Investigational Site
      • Temple, Texas, Forente stater, 76508
        • ImClone Investigational Site
    • Virginia
      • Richmond, Virginia, Forente stater, 23230
        • ImClone Investigational Site
    • Washington
      • Tacoma, Washington, Forente stater, 98405
        • ImClone Investigational Site
    • West Virginia
      • Morgantown, West Virginia, Forente stater, 26506
        • ImClone Investigational Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

To be eligible for the study, subjects must fulfill all of the following criteria and have a complete signed informed consent form.

  • Subjects must have signed an approved informed consent.
  • Subjects with histologically or cytologically documented stage IIIB (supraclavicular lymph node, high neck node, or pleural effusion involvement) or IV NSCLC. Disease must be newly diagnosed or recurrent at least 1 year post adjuvant therapy.
  • Subjects with measurable disease.
  • Subjects with ECOG performance status 0-1.
  • Subjects with asymptomatic brain metastasis are eligible; however, they must have completed radiotherapy/radiosurgery at least 2 weeks prior to enrollment and be off steroids.
  • Radiotherapy must have been completed > 2 weeks prior to enrollment and the subject must have recovered from all adverse effects of prior radiotherapy. No previous irradiation to the only area of measurable disease. New lesions that developed in a previously irradiated area will be allowed.
  • If diagnostic tissue or slides are available for a subject, these must be submitted for testing of EGFR status.
  • Subjects ≥18 years of age.
  • Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 4 weeks after the study in such a manner that the risk of pregnancy is minimized. WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal [defined as amenorrhea ≥12 consecutive months; or women on hormone replacement therapy (HRT) with documented serum follicle stimulating hormone (FSH) level >35mIU/mL]. Even women who are using oral, implanted or injectable contraceptive hormones or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy or practicing abstinence or where partner is sterile (e.g., vasectomy), should be considered to be of child bearing potential. WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to the start of study medication.

  • Subjects with adequate hematologic function defined as: ANC ≥1,500/mm 3 ; WBC

    ≥3,000/mm 3 ; platelets ≥100,000/mm 3 ; and hemoglobin ≥9 g/dL.

  • Subjects with adequate hepatic function defined as: total bilirubin ≤1.5 x upper limit of normal (ULN) or AST ≤2.5 x ULN.
  • Subjects with adequate renal function defined as a serum creatinine level ≤1.5 mg/dL or a creatinine clearance ≥60 cc/minute.

Exclusion Criteria:

Any of the following criteria will make the subject ineligible to participate in this study.

  • WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 4 weeks after the study. Subjects who are men must also agree to use effective contraception.
  • WOCBP using a prohibited contraceptive method.
  • Women who are pregnant or breastfeeding.
  • Women with a positive pregnancy test on enrollment or prior to study drug administration.
  • Subjects who have had prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the subject has been disease-free for 5 years.
  • Subjects with significant history of cardiac disease, i.e., uncontrolled hypertension, unstable angina, uncontrolled congestive heart failure, cardiomyopathy with decreased ejection fraction, myocardial infarction within the past year, or cardiac ventricular arrythmias requiring medication.
  • Subjects with an uncontrolled seizure disorder, or active neurological disease.
  • Subjects with symptomatic brain metastasis. Prohibited Therapies and/or Medications
  • Subjects who have received prior systemic chemotherapy. Subjects with no more than one prior adjuvant regimen for initially diagnosed disease are eligible for the study.
  • Subjects with a history of prior cetuximab or other therapy that specifically and directly targets the EGFR pathway.
  • Subject with prior severe infusion reaction to a monoclonal antibody.
  • Subjects with know allergy to Cremophor EL.
  • Subjects with known peripheral neuropathy (> grade 1).
  • Subjects with prior erythropoietin (i.e., Epogen, Procrit) treatment.
  • Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Arm A (3-week cycle)

Cetuximab was administered weekly at an initial dose (Week 1) of 400 mg/m2 IV infusion and a weekly maintenance dose of 250 mg/m2 IV infusion.

Paclitaxel 225 mg/m2 infused over 180 minutes on Day 1 and subsequently every 3 weeks.

Carboplatin (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 3 weeks.
Biologisk: Cetuximab

(Week 1) of 400 mg/m2 IV infusion and a weekly maintenance dose of 250 mg/m2 IV infusion.

A cycle of therapy was defined as 3 weeks in Arm A and 4 weeks in Arm B.

Andre navn:
  • Erbitux
Legemiddel: Carboplatin
(AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 3 weeks (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 4 weeks.
Andre navn:
  • Paraplatin
Legemiddel: Paclitaxel
225 mg/m2 infused over 180 minutes on Day 1 and subsequently every 3 weeks. OR 100 mg/m2 infused over 180 minutes on Day 1, Day 8 and Day 15 of a 4-week cycle.
Andre navn:
  • Taxol
Aktiv komparator: Arm B (4-week cycle)

Cetuximab was administered weekly at an initial dose (Week 1) of 400 mg/m2 IV infusion and a weekly maintenance dose of 250 mg/m2 IV infusion.

Paclitaxel 100 mg/m2 infused over 180 minutes on Day 1, Day 8 and Day 15 of a 4-week cycle.

Carboplatin (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 4 weeks.
Biologisk: Cetuximab

(Week 1) of 400 mg/m2 IV infusion and a weekly maintenance dose of 250 mg/m2 IV infusion.

A cycle of therapy was defined as 3 weeks in Arm A and 4 weeks in Arm B.

Andre navn:
  • Erbitux
Legemiddel: Carboplatin
(AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 3 weeks (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 4 weeks.
Andre navn:
  • Paraplatin
Legemiddel: Paclitaxel
225 mg/m2 infused over 180 minutes on Day 1 and subsequently every 3 weeks. OR 100 mg/m2 infused over 180 minutes on Day 1, Day 8 and Day 15 of a 4-week cycle.
Andre navn:
  • Taxol

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
To estimate median progression free survival and the progression free survival rate
Tidsramme: 6 months
6 months

Sekundære resultatmål

Resultatmål
Tidsramme
To estimate the overall response rate in each treatment arm
Tidsramme: 6 months
6 months
To estimate median survival and the survival rate at one year in each treatment arm
Tidsramme: 6 months
6 months
To evaluate the toxicity profile of each treatment arm
Tidsramme: 6 months
6 months
To explore the relationship between EGFR expression and the "clinical benefit" received from each treatment regimen
Tidsramme: 6 months
6 months
To evaluate symptom response rate in each treatment arm using the Lung Cancer Subscale (LCS) of the FACT-L
Tidsramme: 6 months
6 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Eli Lilly and Company

Samarbeidspartnere

Bristol-Myers Squibb

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. november 2004

Primær fullføring (Faktiske)

1. april 2007

Studiet fullført (Faktiske)

1. april 2007

Datoer for studieregistrering

Først innsendt

18. november 2004

Først innsendt som oppfylte QC-kriteriene

18. november 2004

Først lagt ut (Anslag)

19. november 2004

Oppdateringer av studieposter

Sist oppdatering lagt ut (Anslag)

9. april 2010

Siste oppdatering sendt inn som oppfylte QC-kriteriene

8. april 2010

Sist bekreftet

1. april 2010

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • CA225-058

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere